CYTORA is a clinical stage stem cell company utilizing a patented platform technology based on human Oral Mucosa Stem Cells (hOMSC) to produce allogeneic therapeutic doses for treating chronic wounds, such as incurable diabetic foot ulcers, and neurodegenerative diseases like Parkinson's and Alzheimer's. This approach leverages the unique regenerative properties of oral mucosa, enabling rapid wound healing and tissue regeneration that is minimally affected by age or diabetes.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic wounds, such as incurable diabetic foot ulcers, present a significant challenge due to impaired healing capabilities, particularly in patients with diabetes or advanced age. Current treatments often prove ineffective, leading to prolonged suffering and potential complications. Neurodegenerative diseases like Parkinson's and Alzheimer's also lack effective regenerative therapies.
Solution
Cytora is developing allogeneic stem cell therapies derived from human Oral Mucosa Stem Cells (hOMSC) to address chronic wounds and neurodegenerative diseases. Their patented platform technology leverages the unique regenerative properties of oral mucosa, which exhibits rapid, scar-free wound healing that is minimally affected by age or diabetes. This approach aims to promote tissue regeneration and accelerate healing in chronic wounds, while also exploring potential therapeutic benefits in neurodegenerative conditions. The hOMSC-based therapies offer a novel approach to stimulate regeneration in tissues where healing is otherwise compromised.
Target Audience
The primary target audience includes patients suffering from chronic wounds, such as incurable diabetic foot ulcers, and individuals affected by neurodegenerative diseases like Parkinson's and Alzheimer's.
Features
- Patented platform technology based on human Oral Mucosa Stem Cells (hOMSC).
- Allogeneic therapeutic doses suitable for treating chronic wounds and neurodegenerative diseases.
- Rapid wound healing and tissue regeneration capabilities derived from oral mucosa.
- Wound healing process minimally affected by age or diabetes.
- Clinical studies in progress for Incurable Diabetic Foot Ulcers (IDFU).
- Clinical studies in progress for Multiple System Atrophy (MSA).